The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri PharmacoEconomics (TyPE) Study
Multiple sclerosis progressively impairs patients’ ability to independently perform activities of daily living, reduces working capacity, and negatively affects social interactions and relationships, imposing a cost for the society. The aim of this study was to explore the impact on society of treat...
Main Authors: | , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
AboutScience Srl
2019-06-01
|
Series: | Global & Regional Health Technology Assessment |
Online Access: | https://doi.org/10.1177/2284240319852956 |
id |
doaj-fba48126858f4a10bdaf116fc4cf07c3 |
---|---|
record_format |
Article |
spelling |
doaj-fba48126858f4a10bdaf116fc4cf07c32020-11-25T01:30:42ZengAboutScience SrlGlobal & Regional Health Technology Assessment2283-57332019-06-01201910.1177/2284240319852956The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri PharmacoEconomics (TyPE) StudyB Polistena0F Spandonaro1R Capra2S Fantaccini3L Santoni4GB Zimatore5C Gasperini6C.R.E.A. Sanità, University of Rome Tor Vergata, Rome, ItalyC.R.E.A. Sanità, University of Rome Tor Vergata, Rome, ItalyMultiple Sclerosis Center, Spedali Civili of Brescia, Brescia, ItalyBiogen Italia S.R.L., Milan, ItalyBiogen Italia S.R.L., Milan, ItalyU.O. Neurology, P.O. Dimiccoli, Barletta, ItalyDepartment of Neurosciences, San Camillo-Forlanini Hospital, Rome, ItalyMultiple sclerosis progressively impairs patients’ ability to independently perform activities of daily living, reduces working capacity, and negatively affects social interactions and relationships, imposing a cost for the society. The aim of this study was to explore the impact on society of treatment of multiple sclerosis with natalizumab in Italian clinical practice. A prospective, observational study was conducted in 24 specialized centers throughout Italy. Direct and indirect costs, as well as the health-related quality of life of patients undergoing treatments, were estimated, while societal impacts were determined using a cost-utility approach. Non-medical direct and indirect costs accounted for 55.7% of the total cost prior to treatment and up to 47.5% after treatment with natalizumab. From the social perspective, greater medical direct costs for second-line drug treatment are nearly offset by savings on non-medical direct costs and by greater productivity, resulting in a +0.5% incremental cost. Assuming a societal perspective, the first year of treatment with natalizumab in real-world clinical practice results in an incremental cost of €2814.8/quality-adjusted life year gained. Multiple sclerosis imposes a considerable burden on patients, their families, and caregivers, stressing the importance of considering the societal perspective in the appraisal process. Treatment with natalizumab shows a noteworthy benefit in social terms.https://doi.org/10.1177/2284240319852956 |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
B Polistena F Spandonaro R Capra S Fantaccini L Santoni GB Zimatore C Gasperini |
spellingShingle |
B Polistena F Spandonaro R Capra S Fantaccini L Santoni GB Zimatore C Gasperini The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri PharmacoEconomics (TyPE) Study Global & Regional Health Technology Assessment |
author_facet |
B Polistena F Spandonaro R Capra S Fantaccini L Santoni GB Zimatore C Gasperini |
author_sort |
B Polistena |
title |
The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri PharmacoEconomics (TyPE) Study |
title_short |
The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri PharmacoEconomics (TyPE) Study |
title_full |
The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri PharmacoEconomics (TyPE) Study |
title_fullStr |
The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri PharmacoEconomics (TyPE) Study |
title_full_unstemmed |
The societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in Italian clinical practice: The Tysabri PharmacoEconomics (TyPE) Study |
title_sort |
societal impact of treatment with natalizumab of relapsing–remitting multiple sclerosis in italian clinical practice: the tysabri pharmacoeconomics (type) study |
publisher |
AboutScience Srl |
series |
Global & Regional Health Technology Assessment |
issn |
2283-5733 |
publishDate |
2019-06-01 |
description |
Multiple sclerosis progressively impairs patients’ ability to independently perform activities of daily living, reduces working capacity, and negatively affects social interactions and relationships, imposing a cost for the society. The aim of this study was to explore the impact on society of treatment of multiple sclerosis with natalizumab in Italian clinical practice. A prospective, observational study was conducted in 24 specialized centers throughout Italy. Direct and indirect costs, as well as the health-related quality of life of patients undergoing treatments, were estimated, while societal impacts were determined using a cost-utility approach. Non-medical direct and indirect costs accounted for 55.7% of the total cost prior to treatment and up to 47.5% after treatment with natalizumab. From the social perspective, greater medical direct costs for second-line drug treatment are nearly offset by savings on non-medical direct costs and by greater productivity, resulting in a +0.5% incremental cost. Assuming a societal perspective, the first year of treatment with natalizumab in real-world clinical practice results in an incremental cost of €2814.8/quality-adjusted life year gained. Multiple sclerosis imposes a considerable burden on patients, their families, and caregivers, stressing the importance of considering the societal perspective in the appraisal process. Treatment with natalizumab shows a noteworthy benefit in social terms. |
url |
https://doi.org/10.1177/2284240319852956 |
work_keys_str_mv |
AT bpolistena thesocietalimpactoftreatmentwithnatalizumabofrelapsingremittingmultiplesclerosisinitalianclinicalpracticethetysabripharmacoeconomicstypestudy AT fspandonaro thesocietalimpactoftreatmentwithnatalizumabofrelapsingremittingmultiplesclerosisinitalianclinicalpracticethetysabripharmacoeconomicstypestudy AT rcapra thesocietalimpactoftreatmentwithnatalizumabofrelapsingremittingmultiplesclerosisinitalianclinicalpracticethetysabripharmacoeconomicstypestudy AT sfantaccini thesocietalimpactoftreatmentwithnatalizumabofrelapsingremittingmultiplesclerosisinitalianclinicalpracticethetysabripharmacoeconomicstypestudy AT lsantoni thesocietalimpactoftreatmentwithnatalizumabofrelapsingremittingmultiplesclerosisinitalianclinicalpracticethetysabripharmacoeconomicstypestudy AT gbzimatore thesocietalimpactoftreatmentwithnatalizumabofrelapsingremittingmultiplesclerosisinitalianclinicalpracticethetysabripharmacoeconomicstypestudy AT cgasperini thesocietalimpactoftreatmentwithnatalizumabofrelapsingremittingmultiplesclerosisinitalianclinicalpracticethetysabripharmacoeconomicstypestudy AT bpolistena societalimpactoftreatmentwithnatalizumabofrelapsingremittingmultiplesclerosisinitalianclinicalpracticethetysabripharmacoeconomicstypestudy AT fspandonaro societalimpactoftreatmentwithnatalizumabofrelapsingremittingmultiplesclerosisinitalianclinicalpracticethetysabripharmacoeconomicstypestudy AT rcapra societalimpactoftreatmentwithnatalizumabofrelapsingremittingmultiplesclerosisinitalianclinicalpracticethetysabripharmacoeconomicstypestudy AT sfantaccini societalimpactoftreatmentwithnatalizumabofrelapsingremittingmultiplesclerosisinitalianclinicalpracticethetysabripharmacoeconomicstypestudy AT lsantoni societalimpactoftreatmentwithnatalizumabofrelapsingremittingmultiplesclerosisinitalianclinicalpracticethetysabripharmacoeconomicstypestudy AT gbzimatore societalimpactoftreatmentwithnatalizumabofrelapsingremittingmultiplesclerosisinitalianclinicalpracticethetysabripharmacoeconomicstypestudy AT cgasperini societalimpactoftreatmentwithnatalizumabofrelapsingremittingmultiplesclerosisinitalianclinicalpracticethetysabripharmacoeconomicstypestudy |
_version_ |
1725090530943041536 |